Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167156 | 0.92 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL11592610 | 0.86 | MMP2 (0.37) | MMP2TSHRMEN1KMT2A | |
| SCHEMBL10215089 | 0.84 | LMNA (0.40) | TSHRKMT2A | |
| SCHEMBL1344130 | 0.82 | ALDH1A1 (0.37) | TSHR | |
| SCHEMBL18090272 | 0.81 | TSHR (0.43) | TSHRMEN1KMT2A | |
| SCHEMBL7754985 | 0.81 | TSHR (0.39) | TSHRMEN1KMT2A | |
| SCHEMBL13813150 | 0.80 | ALDH1A1 (0.35) | — | |
| SCHEMBL6284087 | 0.76 | TSHR (0.48) | TSHRKMT2A | |
| SCHEMBL18090265 | 0.75 | TSHR (0.38) | TSHR | |
| SCHEMBL18090267 | 0.75 | TSHR (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879041-B2 | Saccharide dendritic cluster compounds as inhibitors of BACE-1 | VICTORIA LINK LIMITED (NZ) | 2018-01-30 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | MMP2 885/4885TSHR 4758/4885MEN1 1407/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | MMP2 885/4885TSHR 4758/4885MEN1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.